Jul. 1 at 6:58 PM
$PACB
$ILMN
Strategic Notes #1
Could SPRQ-Nx change Illumina’s strategic incentives regarding PACB
Most ask:
“Would partnering strengthen PacBio too much?”
I think the more important question is:
Would an acquired PACB strengthen one of Illumina’s competitors more than a strengthened independent PACB operating within a mutually beneficial partnership?
Illumina previously tried to acquire PacBio because it viewed HiFi as strategically important. If Spark materially improves the economics and scalability of HiFi, waiting could increases PACB’s bargaining power while also increasing the chance that another major industry player becomes interested.
Viewed this way, a partnership could represent strategic risk management rather than simply accelerating PacBio’s growth.
Strategic hypothesis only—not a prediction.
Disclosure: My analysis. ChatGPT assisted with editing. Not investment advice.
Question: Which assumption is weakest?
